U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

Dateline City:

PRINCETON, N.J.

In clinical trials, ZEPOSIA demonstrated efficacy on a key clinical marker of disease activity – annualized relapse rate (ARR) – as compared to AVONEX ® (interferon beta-1a)1 ,2,3
ZEPOSIA is a sphingosine-1-phosphate (S1P) receptor modulator that requires no label-based first dose observation 1
ZEPOSIA adds to Bristol Myers Squibb’s legacy immunology franchise and marks the first FDA-approved New Drug Application since the Celgene acquisition

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S.
Language:

English

Contact:

Media Inquiries: Media@bms.com 609-252-3345 Susan Francis Susan.francis@bms.com 609-529-0676 Investors: Tim Power Timothy.power@bms.com 609-252-7509

Ticker Slug:

Ticker: BMY Exchange: NYSE

#FDA approves new $BMY oral treatment option for #MultipleSclerosis #MS

read more

Original Source